Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Biomatter logo — Creating proteins with Intelligent Architecture™ for health...

Biomatter

Creating proteins with Intelligent Architecture™ for health and sustainable manufacturing

Founded 2018 Lithuania Lithuania 27 employees Seed Total: $7.00M Biopharma, Biotechnology +2

General Information

Company Name Biomatter
Founded Year 2018
Location Lithuania Lithuania
Employees 27
Industries Biopharma, Biotechnology, Life Sciences +1
Funding Stage Seed
Business Model B2B, White Label, Platform
Revenue Model Project Based, Licensing, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Biomatter. To contact Biomatter, visit biomatter.ai.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Biomatter compare?

A PDF of Biomatter and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Biomatter soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Biomatter

Biomatter, formerly known as Biomatter Designs, is a pioneering synthetic biology company founded in 2018 and headquartered in Lithuania. With its distinctive slogan, "Creating proteins with Intelligent Architecture™ for health and sustainable manufacturing," the company addresses critical needs in the Biopharma, Biotechnology, Life Sciences, and Pharmaceutical industries.

At the core of Biomatter's innovation is its proprietary Intelligent Architecture™ platform, designed to transcend traditional protein engineering challenges and unveil new opportunities in protein design and development.

In its latest funding round on 05 August 2024, the company secured a €6.50M Seed Round investment, supported by notable investors such as Practica Capital, UVC Partners, Metaplanet Holdings, and Inventure. This financial backing underscores investor confidence in Biomatter's potential to drive breakthroughs in health and sustainable manufacturing sectors.

Business keywords: synthetic biology, protein design, protein engineering, enzyme design, enzyme optimization, biocatalysis, biomanufacturing, life sciences, health applications, sustainable manufacturing, Intelligent Architecture™, enzyme discovery, enzyme engineering, API manufacturing, chemical manufacturing

Services & Products

AI-first Enzyme Design Platform
End-to-end Enzyme Solutions
LYNX Enzyme Optimization
Partnership Models and Pricing Schemes

Target Customers

Industrial Biotechnology Companies Biopharmaceutical Firms Chemical Manufacturers Technology Development Partners

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round €6.50M 4
Practica Capital UVC Partners Metaplanet Holdings
Practica Capital, UVC Partners +2
05 Aug 2024
Seed Round €500.00K 2
Practica Capital 70V
Practica Capital, 70V
11 Jan 2021

Biomatter Alternatives & Competitors

View All Alternatives
Biomatter vs
SyntheticGestalt
SyntheticGestalt Japan

Scientific Research by Artificially Intelligent Agents

20 employees
Biotechnology, Pharmaceutical
Compare Biomatter vs SyntheticGestalt
Biomatter vs
64x Bio
64x Bio United States

Enabling next generation medicines.

Series A
21 employees
Biopharma, Biotechnology
Compare Biomatter vs 64x Bio
Biomatter vs
Synbio Technologies
Synbio Technologies United States

Changing the world, one sequence at a time.

25 employees
Biotechnology, Health Care
Also compare with: Biomatter vs Enzymit Enzymit Biomatter vs Antheia, Inc. Antheia, Inc. View all alternatives

FAQ About Biomatter

Creating proteins with Intelligent Architecture™ for health and sustainable manufacturing
Biomatter was founded in 2018.
Biomatter is headquartered in Lithuania.
Biomatter operates in Biopharma, Biotechnology, Life Sciences and Pharmaceutical. Its work centres on synthetic biology, protein design, protein engineering and enzyme design. Its customers include Industrial Biotechnology Companies, Biopharmaceutical Firms and Chemical Manufacturers.
Biomatter has a B2B, White Label and Platform business model. Its revenue comes from Project Based, Licensing and Performance Based.
Biomatter has approximately 27 employees.
Biomatter has completed 2 funding rounds, raising a total of $7.00M. The latest funding stage is Seed.
Biomatter offers: AI-first Enzyme Design Platform, End-to-end Enzyme Solutions, LYNX Enzyme Optimization, Partnership Models and Pricing Schemes.
Top alternatives and competitors to Biomatter include SyntheticGestalt, 64x Bio, Synbio Technologies, Ainnocence, Aminoverse. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Biomatter and SyntheticGestalt are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Biomatter, https://bouncewatch.com/company/biomatter-designs, updated 15 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes